SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs1504982

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma

This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.

NCT03592212 Asthma Drug: Salbutamol
MeSH:Asthma
HPO:Asthma

comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982.

Primary Outcomes

Description: comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982

Measure: pre- and post-bronchodilator VEMS value

Time: Day 0

Secondary Outcomes

Description: To identify other SNPs on PDE4 associated with the response (BDR) to salbutamol in childhood asthma.

Measure: Locating other regions of the PDE4 gene that may be associated with the response to salbutamol by gene mapping (using SNP tags)

Time: Day 0

Description: To identify other genes that could be associated with the phenotype of interest (BDR) by tagging other genes.

Measure: Screening other SNPs (other genes than PDE4) associated with the response to salbutamol in childhood asthma using SNP tags

Time: Day 0


HPO Nodes